Warnex Licenses Epigenomics' Septin9 Marker; Will Offer Colorectal Cancer Dx in Canada

The non-exclusive license grants Warnex the right to establish a PCR-based laboratory-developed test for Septin9 and offer colorectal cancer blood testing services in Canada.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.